Celularity Provides Corporate Update; Says The Acquisition Of Rebound Adds To Our Portfolio Of Placental-Derived Advanced Biomaterial Products, Sales Of Which Through The First Half Of 2024 Were In Excess Of $24M; Guidance Of Expected Combined Net Sales Of Our Advanced Biomaterial Product And Biobanking Businesses To Be In The Range Of $50M-$56M
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO.Dear
